Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | TOP1 | P11387 | 1/20 | 0.53 |
| ▸ | CCR1 | P32246 | 3/20 | 0.50 |
| ▸ | CCR5 | P51681 | 3/20 | 0.50 |
| ▸ | CCR8 | P51685 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | METAP1 | P53582 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506946 | 0.83 | KDM4E (0.50) | KDM4EALDH1A1MAPK1RAB9ACCR1 | |
| SCHEMBL28129410 | 0.83 | KDM4E (0.50) | KDM4EALDH1A1MAPK1RAB9ACCR1 | |
| SCHEMBL30117410 | 0.83 | RAB9A (0.56) | KDM4EALDH1A1MAPK1RAB9ACCR1 | |
| SCHEMBL27642885 | 0.83 | RAB9A (0.50) | KDM4EALDH1A1MAPK1RAB9ACCR1 | |
| SCHEMBL29739308 | 0.83 | KDM4E (0.50) | KDM4EALDH1A1MAPK1RAB9ACCR1 | |
| SCHEMBL23253142 | 0.83 | KDM4E (0.50) | KDM4EALDH1A1MAPK1RAB9ACCR1 | |
| SCHEMBL20469169 | 0.83 | KDM4E (0.50) | KDM4EALDH1A1MAPK1RAB9ACCR1 | |
| SCHEMBL29901515 | 0.83 | RAB9A (0.50) | KDM4EALDH1A1MAPK1RAB9ACCR1 | |
| SCHEMBL28714020 | 0.82 | TOP1 (0.51) | KDM4EALDH1A1MAPK1RAB9ATOP1 | |
| SCHEMBL28463441 | 0.82 | TOP1 (0.51) | KDM4EALDH1A1MAPK1RAB9ATOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | claimed |
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-10-29 | — | — | US | claimed |
| US-20190105307-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2019-04-11 | — | — | US | claimed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | claimed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | claimed |
| CN-103384668-A | Novel compounds and compositions for inhibiting NAMPT | FORMA THERAPEUTICS INC | 2013-11-06 | — | — | CN | claimed |
| EP-2611804-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-12312353-B2 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2025-05-27 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20230002388-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2022-08-23 | — | — | US | disclosed |
| EP-1366054-B1 | METHOD FOR THE PRODUCTION OF HIGHLY PURE, TRIS-ORTHO-METALATED ORGANO-IRIDIUM COMPOUNDS | COVION ORGANIC SEMICONDUCTORS (DE) | 2005-04-06 | — | — | EP | disclosed |
| US-20040077862-A1 | Method for the production of highly pure, tris-ortho-metalated organo-iridium compounds | MERCK PATENT GMBH (DE) | 2004-04-22 | — | — | US | disclosed |
| EP-1366054-A1 | METHOD FOR THE PRODUCTION OF HIGHLY PURE, TRIS-ORTHO-METALATED ORGANO-IRIDIUM COMPOUNDS | Covion Organic Semiconductors GmbH (DE) | 2003-12-03 | — | — | EP | disclosed |
| US-20030040627-A1 | Luminescent organometallic compound and light emitting device | SANYO ELECTRIC CO., LTD. (JP) | 2003-02-27 | — | — | US | disclosed |
| CN-1397559-A | Luminous organic intermetallic compound and luminous element | SANYO ELECTRIC CO (JP) | 2003-02-19 | — | — | CN | disclosed |
| WO-2002060910-A1 | METHOD FOR THE PRODUCTION OF HIGHLY PURE, TRIS-ORTHO-METALATED ORGANO-IRIDIUM COMPOUNDS | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312353-B2 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NSD2, NSD1, NSD3 | KDM4E 769/4885ALDH1A1 3642/4885MAPK1 2058/4885 |
| US-20190105307-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | KDM4E 2133/4885ALDH1A1 1273/4885MAPK1 2004/4885 |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | KDM4E 1401/4885ALDH1A1 984/4885MAPK1 1884/4885 |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NSD2, NSD1, NSD3 | KDM4E 769/4885ALDH1A1 3642/4885MAPK1 2058/4885 |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | KDM4E 2133/4885ALDH1A1 1273/4885MAPK1 2004/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | KDM4E 1325/4885ALDH1A1 994/4885MAPK1 1991/4885 |
| US-20040077862-A1 | Method for the production of highly pure, tris-ortho-metalated organo-iridium compounds | CDK8, IPO8, PAX8 | KDM4E 1988/4885ALDH1A1 2935/4885MAPK1 2470/4885 |
| US-20030040627-A1 | Luminescent organometallic compound and light emitting device | IK, CRY1, LBR | KDM4E 3641/4885ALDH1A1 2337/4885MAPK1 3649/4885 |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | KDM4E 2133/4885ALDH1A1 1273/4885MAPK1 2004/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | KDM4E 1325/4885ALDH1A1 994/4885MAPK1 1991/4885 |
| US-20230002388-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | NSD2, NSD1, NSD3 | KDM4E 769/4885ALDH1A1 3642/4885MAPK1 2058/4885 |
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | KDM4E 1325/4885ALDH1A1 994/4885MAPK1 1991/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | KDM4E 2133/4885ALDH1A1 1273/4885MAPK1 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.